2023
Circulating NK cells establish tissue residency upon acute infection of skin and mediate accelerated effector responses to secondary infection
Torcellan T, Friedrich C, Doucet-Ladevèze R, Ossner T, Solé V, Riedmann S, Ugur M, Imdahl F, Rosshart S, Arnold S, de Agüero M, Gagliani N, Flavell R, Backes S, Kastenmüller W, Gasteiger G. Circulating NK cells establish tissue residency upon acute infection of skin and mediate accelerated effector responses to secondary infection. Immunity 2023, 57: 124-140.e7. PMID: 38157853, PMCID: PMC10783803, DOI: 10.1016/j.immuni.2023.11.018.Peer-Reviewed Original ResearchConceptsNK cellsTrNK cellsAcute infectionTissue residencySecondary infectionTissue-resident NK cellsConventional NK cellsDistinct developmental requirementsNK cell responsesNatural killer cellsTranscriptional regulator Blimp1Effector cellsKiller cellsCNK cellsPrevious infectionEffector responsesEffector functionsBacterial infectionsCell responsesInfectionRestricted expressionTerms of ontogenyTissueCell formationHuman tissues
2022
HIV-1 Vpu restricts Fc-mediated effector functions in vivo
Prévost J, Anand S, Rajashekar J, Zhu L, Richard J, Goyette G, Medjahed H, Gendron-Lepage G, Chen H, Chen Y, Horwitz J, Grunst M, Zolla-Pazner S, Haynes B, Burton D, Flavell R, Kirchhoff F, Hahn B, Smith A, Pazgier M, Nussenzweig M, Kumar P, Finzi A. HIV-1 Vpu restricts Fc-mediated effector functions in vivo. Cell Reports 2022, 41: 111624. PMID: 36351384, PMCID: PMC9703018, DOI: 10.1016/j.celrep.2022.111624.Peer-Reviewed Original ResearchConceptsAntibody-dependent cellular cytotoxicityEffector functionsFc-mediated effector functionsHIV-1-infected cellsWild-type virusCorrelates of protectionRV144 vaccine trialHIV-1 infectionNon-neutralizing antibodiesFc effector functionsCell surface CD4Viral envelope glycoproteinsViral loadHumanized miceHumoral responseVaccine trialsCellular cytotoxicityHIV-1 VpuVpu expressionEnvelope glycoproteinInfected cellsNnAbsVirusVpuAdministration